Khaled Q A Abdullah1,2, Jana V Roedler1, Juergen Vom Dahl1, Istvan Szendey1, Hendrik Haake1, Lars Eckardt3, Albert Topf4, Bernhard Ohnewein4, Peter Jirak4, Lukas J Motloch4, Bernhard Wernly4,5,6, Robert Larbig1,3. 1. Division of Cardiology, Hospital Maria Hilf Mönchengladbach, Mönchengladbach, Germany. 2. Department of Cardiology, RWTH Aachen University, Aachen, Germany. 3. Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany. 4. Clinic II for Internal Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. 5. Department of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria. 6. Center for Public Health and Healthcare Research, Paracelsus Medical University, Salzburg, Austria.
Abstract
BACKGROUND: Critically ill patients with cardiogenic shock could benefit from ventricular assist device support using the Impella microaxial blood pump. However, recent studies suggested Impella not to improve outcomes. We, therefore, evaluated outcomes and predictors in a real-world scenario. METHODS: In this retrospective single-center trial, 125 patients suffering from cardiac arrest/cardiogenic shock between 2008 and 2018 were analyzed. 93 Patients had a prior successful cardiopulmonary resuscitation. The primary endpoint was hospital mortality. Associations of covariates with the primary endpoint were assessed by univariable and multivariable logistic regression. Adjusted odds ratios (aOR) and optimal cut-offs (using Youden index) were obtained. RESULTS: Hospital mortality was high (81%). Baseline lactate was 4.7mmol/L [IQR = 7.1mmol/L]. In multivariable logistic regression, only age (aOR 1.13 95%CI 1.06-1.20; p<0.001) and lactate (aOR 1.23 95%CI 1.004-1.516; p = 0.046) were associated with hospital mortality, and the respective optimal cut-offs were >3.3mmol/L and age >66 years. Patients were retrospectively stratified into three risk groups: Patients aged ≤66 years and lactate ≤3.3mmol (low-risk; n = 22); patients aged >66 years or lactate >3.3mmol/L (medium-risk; n = 52); and patients both aged >66 years and lactate >3.3mmol/L (high-risk, n = 51). Risk of death increased from 41% in the low-risk group, to 79% in the medium risk group and 100% in the high-risk group. The predictive abilities of this model were high (AUC 0.84; 95% 0.77-0.92). CONCLUSION: Mortality was high in this real-world collective of severely ill cardiogenic shock patients. Better patient selection is warranted to avoid unethical use of Impella. Age and lactate might help to improve patient selection.
BACKGROUND:Critically illpatients with cardiogenic shock could benefit from ventricular assist device support using the Impella microaxial blood pump. However, recent studies suggested Impella not to improve outcomes. We, therefore, evaluated outcomes and predictors in a real-world scenario. METHODS: In this retrospective single-center trial, 125 patients suffering from cardiac arrest/cardiogenic shock between 2008 and 2018 were analyzed. 93 Patients had a prior successful cardiopulmonary resuscitation. The primary endpoint was hospital mortality. Associations of covariates with the primary endpoint were assessed by univariable and multivariable logistic regression. Adjusted odds ratios (aOR) and optimal cut-offs (using Youden index) were obtained. RESULTS: Hospital mortality was high (81%). Baseline lactate was 4.7mmol/L [IQR = 7.1mmol/L]. In multivariable logistic regression, only age (aOR 1.13 95%CI 1.06-1.20; p<0.001) and lactate (aOR 1.23 95%CI 1.004-1.516; p = 0.046) were associated with hospital mortality, and the respective optimal cut-offs were >3.3mmol/L and age >66 years. Patients were retrospectively stratified into three risk groups: Patients aged ≤66 years and lactate ≤3.3mmol (low-risk; n = 22); patients aged >66 years or lactate >3.3mmol/L (medium-risk; n = 52); and patients both aged >66 years and lactate >3.3mmol/L (high-risk, n = 51). Risk of death increased from 41% in the low-risk group, to 79% in the medium risk group and 100% in the high-risk group. The predictive abilities of this model were high (AUC 0.84; 95% 0.77-0.92). CONCLUSION:Mortality was high in this real-world collective of severely ill cardiogenic shockpatients. Better patient selection is warranted to avoid unethical use of Impella. Age and lactate might help to improve patient selection.
Authors: Francesco Burzotta; Carlo Trani; Sagar N Doshi; Jonathan Townend; Robert Jan van Geuns; Patrick Hunziker; Bernhard Schieffer; Konstantinos Karatolios; Jacob Eifer Møller; Flavio L Ribichini; Andreas Schäfer; José P S Henriques Journal: Int J Cardiol Date: 2015-07-30 Impact factor: 4.164
Authors: K Lackermair; S Sattler; B C Huber; U Grabmaier; L T Weckbach; A Bauer; H D Theiss; J Hausleiter; J Mehilli; S Massberg; S Brunner Journal: Int J Cardiol Date: 2016-06-14 Impact factor: 4.164
Authors: Maryna Masyuk; Bernhard Wernly; Michael Lichtenauer; Marcus Franz; Bjoern Kabisch; Johanna M Muessig; Georg Zimmermann; Alexander Lauten; P Christian Schulze; Uta C Hoppe; Malte Kelm; Jan Bakker; Christian Jung Journal: Intensive Care Med Date: 2018-11-26 Impact factor: 17.440
Authors: Anthony Lemaire; Mark B Anderson; Leonard Y Lee; Peter Scholz; Thomas Prendergast; Andrew Goodman; Ann Marie Lozano; Alan Spotnitz; George Batsides Journal: Ann Thorac Surg Date: 2013-10-01 Impact factor: 4.330
Authors: Alexander Lauten; Annemarie E Engström; Christian Jung; Klaus Empen; Paul Erne; Stéphane Cook; Stephan Windecker; Martin W Bergmann; Roland Klingenberg; Thomas F Lüscher; Michael Haude; Dierk Rulands; Christian Butter; Bengt Ullman; Laila Hellgren; Maria Grazia Modena; Giovanni Pedrazzini; Jose P S Henriques; Hans R Figulla; Markus Ferrari Journal: Circ Heart Fail Date: 2012-12-04 Impact factor: 8.790
Authors: Miriam Abaunza; Loay S Kabbani; Timothy Nypaver; Adam Greenbaum; Praveen Balraj; Sherazuddin Qureshi; Mohammed A Alqarqaz; Alexander D Shepard Journal: J Vasc Surg Date: 2015-06-06 Impact factor: 4.268
Authors: Hymie Habib Chera; Menachem Nagar; Nai-Lun Chang; Carlos Morales-Mangual; George Dous; Jonathan D Marmur; Muhammad Ihsan; Paul Madaj; Yitzhak Rosen Journal: Expert Rev Med Devices Date: 2018-03-30 Impact factor: 3.166
Authors: Michael Lichtenauer; Bernhard Wernly; Bernhard Ohnewein; Marcus Franz; Bjoern Kabisch; Johanna Muessig; Maryna Masyuk; Alexander Lauten; Paul Christian Schulze; Uta C Hoppe; Malte Kelm; Christian Jung Journal: Int J Mol Sci Date: 2017-09-02 Impact factor: 5.923